Abstract 32P
Background
There is an urgent need for biomarkers to tailor neoadjuvant treatment (NAT) in early triple-negative breast cancer (eTNBC). The characterization of circulating immune subsets could provide additional information which, added to other factors, may guide clinical decisions.
Methods
In this non-randomized prospective study, patients (pt) were treated with chemotherapy (docetaxel/carboplatin or sequential paclitaxel/carboplatin with doxorubicin/cyclophosphamide) with or without pembrolizumab. Immune cell subsets were analyzed in blood by multicolor flow cytometry (MFC). Adjusted paired 2-way ANOVA was done to compare immune subsets. In this first analysis, we report the frequencies of T cell subsets before and 21 days after completing NAT, and their relationship with pathological response.
Results
15 pt achieved pathological complete response (pCR) while 6 had a RCB score of II-III. Significant differences emerged between pCR (responders) and RCB (non-responders) after NAT (Table). Non-responders presented higher drops in total lymphocytes and CD4 cells (p > 0.05). All pt increased CD8 cells, being significant only in responders (p = 0.013). CD8 subsets exhibited distinct behavior based on response. After NAT, responders showed lower activated CD8 cells, whereas non-responders had the opposite trend. Post-NAT activated CD8 cells were lower in responders (p = 0.048). An opposing pattern was observed in the dynamics of the naïve and effector memory CD8 cells (p > 0.05). In the CD4 population, after NAT all pt showed decreased activated CD4 cells. These changes were deeper and significant in responders (p = 0.048). There were no significant differences between responders and non-responders in other CD4 subsets. Table: 32P
% of cells after NAT according to response
Baseline | Post-NAT | |||||
pCR | RCB II – III | P value | pCR | RCB II – III | P value | |
Lymphocytes | 19.1 | 17.9 | 0.99 | 18.1 | 11.5 | 0.44 |
CD4+ | 38,9 | 40,1 | 0.99 | 39.3 | 32.1 | 0.36 |
Activated | 68.3 | 78.5 | 0.5 | 54.6 | 72.6 | 0.045 |
Inactivated | 31.3 | 20.4 | 0.44 | 44.6 | 26.4 | 0.039 |
Naïve | 30.3 | 45.4 | 0.16 | 19.7 | 28.1 | 0.62 |
Effector | 2.1 | 2.2 | 0.99 | 3.1 | 5.1 | 0.99 |
Effector memory | 17.5 | 12.4 | 0.89 | 26.8 | 16.1 | 0.41 |
CD8+ | 16.9 | 13.2 | 0.9 | 26.2 | 20.9 | 0.63 |
Activated | 41.3 | 40 | 0.9 | 28.8 | 49.3 | 0.048 |
Inactivated | 45.5 | 48.9 | 0.9 | 53.3 | 39.7 | 0.32 |
Naïve | 21 | 23.4 | 0.9 | 13.1 | 29.9 | 0.15 |
Effector | 31.9 | 37.2 | 0.9 | 24.2 | 29.6 | 0.9 |
Effector memory | 31.9 | 31.1 | 0.9 | 36.3 | 20.1 | 0.18 |
Conclusions
In this study, there were significant differences in the peripheral T cell subsets based on NAT response, suggesting that there may be a systemic immune activation that could impact disease control. Further research is warranted to validate and amplify these observations.
Legal entity responsible for the study
The authors.
Funding
Instituto de Salud Carlos III (ISCIII) PI22/01346, cofinanciado por la Unión Europea.
Disclosure
I. Echavarria Diaz-Guardamino: Financial Interests, Personal, Advisory Board: Lilly, AstraZeneca; Financial Interests, Personal, Invited Speaker: Roche, Teva, Novartis, Pfizer, Lilly. Y. Jerez Gilarranz: Financial Interests, Personal, Invited Speaker: Daiichi Sankyo, Novartis, Roche, Pfizer. F. Moreno Anton: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Daiichi Sankyo, MSD, Gilead; Financial Interests, Institutional, Research Grant: Pfizer. J.î García Saenz: Financial Interests, Personal, Advisory Board: Seagen, Gilead; Financial Interests, Personal, Speaker, Consultant, Advisor: Sanofi, Novartis, Celgene, Lilly, Eisai, AstraZeneca, MSD, Pierre Fabre, Daiichi Sankyo; Financial Interests, Personal and Institutional, Research Funding: AstraZeneca; Financial Interests, Personal, Other, Travel: Novartis, Roche, Pfizer. C. Bueno Muiño: Financial Interests, Personal, Invited Speaker: Novartis, Daiichi Sankyo, AstraZeneca, GSK, Lilly; Financial Interests, Personal, Advisory Board: Pfizer. T. Massarrah: Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Roche, GSK; Financial Interests, Personal, Other, Travel: Novartis, AstraZeneca. M. Martin Jimenez: Financial Interests, Personal, Research Grant: PUMA; Financial Interests, Personal, Advisory Board: Lilly, Sanofi, Novartis, Seagen, Roche, AstraZeneca, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Roche, Seagen, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo; Financial Interests, Personal, Leadership Role: GEICAM, TRIO. S. Lopez-Tarruella Cobo: Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, Novartis, Roche, Pfizer, Veracyte, Pierre Fabre, Lilly, Seagen, Daiichi Sankyo, Europe GmbH, Gilead Sciences, MSD, GSK. All other authors have declared no conflicts of interest.
Resources from the same session
205P - Advancing pre-clinical functional tests with immune-responsive Precision Cut Bladder Tumor Slices (PCTS)
Presenter: Sarah Richtmann
Session: Poster Display session
Resources:
Abstract
206P - Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Presenter: Yi Hua Low
Session: Poster Display session
Resources:
Abstract
207P - ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
Presenter: Yunhuan Liu
Session: Poster Display session
Resources:
Abstract
208P - Targeting pro-tumor TAMs to improve immune checkpoint response of advanced bladder cancer
Presenter: Marine Leblond
Session: Poster Display session
Resources:
Abstract
209P - Mapping the landscape of immune cells for optimal index calculation using AI-powered image analysis of multiplexed immunohistochemistry in breast cancer patients
Presenter: Patricia Nielsen
Session: Poster Display session
Resources:
Abstract
210P - Precision immuno-oncology strategies to overcome drug resistance in non-small cell lung cancer
Presenter: Heidi Haikala
Session: Poster Display session
Resources:
Abstract
211P - Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis
Presenter: Haoxin Peng
Session: Poster Display session
Resources:
Abstract
212P - YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
Presenter: Zhehui Zhu
Session: Poster Display session
Resources:
Abstract
214P - DNA-damaging therapies trigger transcriptome and metabolism changes in peripheral NK cells of SCLC patients
Presenter: Caterina de Rosa
Session: Poster Display session
Resources:
Abstract
215P - Differential spatial gene expression and clinicopathologic characteristics are associated with exceptional response to immune checkpoint inhibition in recurrent/metastatic head and neck cancer
Presenter: Niki Gavrielatou
Session: Poster Display session
Resources:
Abstract